Loading
BRCA Gene Mutations in Cancer / Ovarian Cancer Diagnosis and Treatment · Journal article
Scholarly Review . · September 4, 2026
A consensus or society position rather than new primary data.
This is a literature review that synthesizes published evidence on olaparib monotherapy and olaparib–durvalumab combination therapy for BRCA-mutated ovarian and breast cancer, with emphasis on the founder mutation BRCA1:c.5470_5477del in the Chinese Han population. The review identifies combination therapy as promising but does not present original efficacy data, prospective rates, or head-to-head trial results.
Narrative literature review. Published literature on BRCA-mutated ovarian and breast cancer and therapies including PARP inhibitors and immunotherapy combinations. Intervention: Literature review of olaparib and durvalumab combination therapy, olaparib monotherapy, and other regimens for BRCAm cancer.
BRCA1:c.5470_5477del founder mutation identified in ovarian and breast cancer patients in Chinese Han population Olaparib monotherapy and chemotherapy exhibit benefits in BRCAm ovarian and breast cancer Olaparib and durvalumab combination shown superior results compared to olaparib alone in multiple trials
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A literature review synthesizing current evidence on PARP inhibitor and immunotherapy combinations for BRCA-mutated cancers, offering clinical perspective rather than reporting original trial data.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Mutations in BRCA1 and BRCA2, two genes that encode proteins vital to DNA repair processes, are associated with many cancers, including breast and ovarian cancer, as well as homologous recombination deficiency. BRCA mutations are linked with earlier diagnoses and can heavily influence prognosis, with mortality risks rising alongside age. Recently, in the Chinese Han population, a prevalent founder mutation, BRCA1:c.5470_5477del, was discovered in ovarian and breast cancer patients. For BRCA-mutated (BRCAm) ovarian and breast cancer cases, current therapies like chemotherapy and Poly (ADP-ribose) polymerase, or PARP, inhibitors exhibit benefits, with olaparib monotherapy being particularly notable. However, olaparib and durvalumab have shown superior results compared to olaparib alone in multiple trials, establishing the combination therapy as a promising alternative that promotes an immune response. Meanwhile, other emerging combination regimens have also shown favorable outcomes. This paper highlights a potential alternative to olaparib monotherapy for the treatment of founder mutation BRCA1:c.5470_5477del, and reviews current progress and prospective approaches for BRCAm ovarian and breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.